Drug Trial Radar · NCT04254978
Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)
Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Sep 8, 2020
Primary completion
Mar 23, 2023
Study completion Mar 23, 2023
Sponsor
- Lead sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Feb 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2b open label study of an orally administered LSD1 inhibitor, Bomedemstat (MK-3543, formerly called IMG-7289), in patients with essential thrombocythemia. This study investigates the following: * The safety and tolerability of Bomedemstat * The pharmacodynamic effect of Bomedemstat
Conditions
- Essential Thrombocythemia
Interventions
BomedemstatDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 30 months
- Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 28 months
- Percentage of Participants With Platelet Count ≤400 k/μL at Day 169Time frame: Up to day 169
Locations
26 sites in 7 countries. Site status is shown where the registry gives one.
Local Institution
Jacksonville, Florida
Local Institution
Ann Arbor, Michigan
Local Institution
New York, New York
Local Institution
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
Local Institution
Pittsburgh, Pennsylvania
Local Institution
Seattle, Washington
Local Institution
Herston, Brisbane, Australia
Local Institution
Camperdown, New South Wales, Australia
Local Institution
St Leonards, New South Wales, Australia
Local Institution
Southport, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Local Institution
Clayton, Victoria, Australia
Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ)
Essen, Germany
Local Institution
Jena, Germany
Local Institution
Hong Kong, Hong Kong
Local Institution
Alessandria, Italy
Local Institution
Bologna, Italy
CRIMM; Centro Ricerca e Innovazione delle Malattia Mieloproliferative, Azienda ospedaliera Universitaria Careggi
Florence, Italy
Local Institution
Varese, Italy
Local Institution
Auckland, New Zealand
Middlemore Hospital
Auckland, New Zealand
Local Institution
London, United Kingdom
Guys and St Thomas Hospital
London, United Kingdom
Local Institution
London, United Kingdom
Local Institution
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.